STRO - SUTRO BIOPHARMA, INC.

19.7
-0.845   -4.289%

Share volume: 90,919
Last Updated: 03-03-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.31%

PREVIOUS CLOSE
CHG
CHG%
$20.54
-0.85
-0.04%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
10%
Profitability 0%
Dept financing 12%
Liquidity 37%
Performance 13%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-3.76%
1 Month
32.30%
3 Months
110.02%
6 Months
1,831.37%
1 Year
1,287.32%
2 Year
311.27%
Key data
Stock price
$19.70
P/E Ratio 
0.00
DAY RANGE
$18.65 - $20.52
EPS 
-$2.55
52 WEEK RANGE
$0.52 - $20.93
52 WEEK CHANGE
$1,348.53
MARKET CAP 
73.618 M
YIELD 
N/A
SHARES OUTSTANDING 
85.135 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-12-2025
BETA 
3.65
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$79,919
AVERAGE 30 VOLUME 
$126,730
Company detail
CEO: William J. Newell
Region: US
Website: sutrobio.com
Employees: 240
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Sutro Biopharma, Inc. focuses on creating protein therapeutics for cancer and autoimmune disorders. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma.

Recent news